Pol Ind. la Mina Avenida de los Reyes, 1
70 articles with PharmaMar S.A.
PharmaMar announces positive results in its lurbinectedin monotherapy trial for small cell lung cancer
PharmaMar (PHM:MSE) today announced that its Phase II trial of lurbinectedin as a single agent for the treatment of relapsed small cell lung cancer (SCLC) has achieved its primary endpoint, by both investigator review and IRC (Independent Review Committee).
PharmaMar’s Zepsyre® ATLANTIS trial in small-cell lung cancer will be an oral presentation at the IASLC's Targeted Therapies annual meeting
This specialized meeting is designed to provide information about ongoing clinical trials of the newest and most promising therapies for lung cancer.
The U.S. Food and Drug Administration (FDA) Has Granted Orphan Drug Designation to PharmaMar's Lurbinectedin
PharmaMar (MCE: PHM) announces that lurbinectedin has been granted orphan drug status by the FDA for the treatment of small cell lung cancer.
ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160 hospital centers in 20 countries
PharmaMar Signs a Commercialization and Distribution License Agreement for Aplidin® With Pint Pharma International
PharmaMar has announced today the signing of a commercialization and distribution license agreement with Pint Pharma International, S.A.
PharmaMar Presents in Oral Session at ASCO: The ADMYRE Study's Adjusted Overall Survival With Plitidepsin
PharmaMar has presented how crossover has had an influence on the overall survival of the ADMYRE trial.
PharmaMar Presents New Results with Lurbinectedin as a Single Agent in Patients with Recurrent Small-cell Lung Cancer at ASCO 2018
PharmaMar announced new data on the recurrent small-cell lung cancer patients cohort of the phase II basket study with lurbinectedin as a single agent, will be presented at the American Society of Clinical Oncology (ASCO) annual meeting.
Positive Recommendation of IDMC to Zepsyre® to Continue the Phase III Trial Within Small-cell Lung Cancer (ATLANTIS)
PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has notified the Company of its recommendation that the Phase III (ATLANTIS) trial currently under way with Zepsyre(R) (lurbinectedin, PM1183) in combination with doxorubicin in small-cell lung cancer patients should continue without any changes.
PharmaMar (MCE: PHM) has presented during the AACR meeting (American Association for Cancer Research) in Chicago new data about how plitidepsin works on the tumor cells.
PharmaMar Has Published the Results of its Antibody Conjugate Active in Breast, Ovarian and Gastric Cancers that Express HER2
PharmaMar has announced the positive results of MI130004, a novel antibody conjugate combining trastuzumab with PM050489, a molecule of marine origin.
PharmaMar Licenses Fully Synthetic Marine-Derived Payloads to Seattle Genetics for Use in Drug Conjugates
According to the terms of the agreement, PharmaMar receives an upfront payment of 5,000,000 US dollars on signing, followed by development milestones if a product enters clinical development conducted by Seattle Genetics.
PharmaMar has announced the initiation of the re-examination process by the EMA for Aplidin for the indication of relapsed and refractory multiple myeloma.
PharmaMar Signs a Commercialization and Distribution License Agreement for Aplidin (plitidepsin) With Megapharm in Israel
PharmaMar has announced today a commercialization and distribution license agreement with Megapharm for the marine-derived anticancer drug Aplidin in Israel and the territory known as the Palestinian Authority.
Plitidepsin (PharmaMar) Shows Activity Against the Cells Responsible for the Destruction of Bone in Myeloma Multiple
PharmaMar presented new preclinical data on plitidepsin showing how it regulates the viability and function of bone cells in combination with other anti-multiple myeloma drugs.
PharmaMar Presents Positive Results of the Pivotal Phase III Trial With Plitidepsin in Multiple Myeloma During the ASH Meeting
With regards to overall survival, a statistically significantly superior increase in the plitidepsin plus dexamethasone arm was observed according to the two-stage Latimer et al method.
Phase III Trial With Zepsyre in Small-Cell Lung Cancer (ATLANTIS) to Continue on the Basis of Positive Recommendation by IDMC
[15-November-2017] MADRID, November 15, 2017 /PRNewswire/ -- PharmaMar (MCE:PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has notified the Company of its recommendation that the Phase III (ATLANTIS) trial currently under way with Zepsyre(R) (PM1183) in combination with doxorubicin in small-cell lung cancer patients should continue without
PharmaMar Presents Positive Results From a Phase II Study of lurbinectedin in Ewing's Sarcoma at the CTOS International Congress
PharmaMar has presented positive results from a Phase II study of lurbinectedin in Ewing's sarcoma at the CTOS's International Congress that took place in Hawaii from the 8th to the 11th of November.
Under the terms of the agreement, PharmaMar receives a non-disclosed upfront payment and will be eligible for additional remunerations upon achieving regulatory and sales milestones.
PharmaMar Announces Partnership With 8th National Race to End Women's Cancer in Support of End Women's Cancer Weekend" in Washington D.C.
The Race features a 5K run and a 1-mile walk in downtown Washington, DC along historical Pennsylvania Avenue, NW, on Sunday morning, Nov. 5.
PharmaMar Release: Final Data on Phase I/II in Small-cell Lung Cancer with Zepsyre Presented at the IASCLC 18th World Conference on Lung Cancer in Japan
PharmaMar has presented updated data from Zepsyre Phase I/II trials in relapse small cell lung cancer in an oral presentation at the International Association for the Study of Lung Cancer (IASLC), at 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan.